Viewing StudyNCT00080782

Home Icon Home Search Icon Search Alerts Icon Stocks Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs eRecord Icon eRecord
Main Search All Studies All Organizations Report Bug
View Study With Definitions
Ignite Creation Date: 2024-05-05 @ 11:35 AM
Last Modification Date: 2024-10-26 @ 9:10 AM
Study NCT ID: NCT00080782
Status: TERMINATED
Last Update Posted: 2018-10-31
First Post: 2004-04-07
Brief Title: Doxorubicin and Strontium-89 With or Without Celecoxib in Treating Patients With Progressive Androgen-Independent Prostate Cancer and Bone Metastases
Sponsor: MD Anderson Cancer Center
Organization: MD Anderson Cancer Center
Overview Dates Organization Conditions Design Enrollment Locations Outcomes

Conditions & Keywords Data

Conditions:
Name
Prostate Cancer
Metastatic Cancer
Keywords:
Name View
recurrent prostate cancer View
stage IV prostate cancer View
bone metastases View
Progressive Androgen-Independent Prostate Cancer View
Metastron View
Sr-89 View
Strontium-89 View
strontium chloride Sr 89 View
Celecoxib View
Celebrex View
Doxorubicin View
Rubex View
Adriamycin View